Website profile

Endpoints News

Biotech and pharma business news, with a focus on the science, people and money that drive the industry.

  • 94articles · 30d
  • 1+ day agolatest article
  • Aug 17, 2026earliest in window
  • 95%with images
  • 86avg words
articles per day
Categories
  • Health & Wellness 74
  • Medical 63
  • Science & Technology 31
  • Health 30
  • Economy, Business & Finance 27
  • Finance & Business 21
  • Business & Industrial 15
  • Science & Nature 7

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Endpoints News
endpoints.news > akeso-details-survival-win-for-its-pd-1xvegf-drug-versus-keytruda

Akeso details survival win for its PD-1xVEGF drug versus Keytruda

1+ day, 11+ hour ago   (76+ words) Endpoints News Ake­so de­tails sur­vival win for its PD-1xVEGF drug ver­sus Keytru­da Ake­so and Sum­mit Ther­a­peu­tics claimed a key win over Keytru­da at the start of Sep­tem­ber,…...

Endpoints News
endpoints.news > cancer-biotech-twostep-gets-62-5m-to-take-twist-on-adcs-into-clinic

Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic

5+ day, 1+ hour ago   (92+ words) Endpoints News Ex­clu­sive: Can­cer biotech TwoStep gets $62.5M to take twist on AD­Cs in­to clin­ic Pfiz­er and Mer­ck KGaA’s ven­ture groups are back­ing a nim­ble can­cer start­up tak…...

Endpoints News
endpoints.news > tyra-claims-phase-2-win-in-bladder-cancer-will-advance-drug-to-pivotal-trial

Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data

5+ day, 1+ hour ago   (81+ words) Endpoints News Tyra finds ray of sun­shine in oth­er­wise cloudy Phase 2 blad­der can­cer da­ta Tyra Bio­sciences wants to chal­lenge John­son & John­son in a low-risk form of blad­der can­cer....

Endpoints News
endpoints.news > inhibrx-plots-ox40-agonist-cancer-vaccine-studies-from-early-next-year

Inhibrx opens door to cancer vaccine combo for its OX40 agonist

6+ day, 1+ hour ago   (154+ words) Endpoints News We value your privacy We use third-party cookies that help us analyze how you use this website and store your preferences. However, you can opt out of these cookies by checking "Do Not Sell or Store My Personal…...

Endpoints News
endpoints.news > brainchild-bio-gets-116m-for-trial-of-pediatric-brain-tumor-car-t

BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T

6+ day, 1+ hour ago   (81+ words) Endpoints News Brain­Child Bio gets $116M for piv­otal tri­al of pe­di­atric brain tu­mor CAR-T A Seat­tle biotech try­ing to flip the script on CAR-T cell ther­a­pies — mak­ing them akin to…...

Endpoints News
endpoints.news > ers26-roivant-reports-phase-2-win-for-lung-disease-drug-that-it-got-from-bayer

Roivant reports Phase 2 win for lung disease drug that it got from Bayer

6+ day, 2+ hour ago   (151+ words) #ERS26: Roivant reports Phase 2 win for lung disease drug that it got from Bayer Endpoints News We value your privacy We use third-party cookies that help us analyze how you use this website and store your preferences. However, you can opt…...

Endpoints News
endpoints.news > fda-approves-astrazenecas-oral-serd-for-breast-cancer-despite-negative-adcomm-vote

FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote

6+ day, 19+ hour ago   (82+ words) Endpoints News FDA ap­proves As­traZeneca’s oral SERD for breast can­cer de­spite neg­a­tive ad­comm vote As­traZeneca clinched an FDA ac­cel­er­at­ed ap­proval for its oral SERD in cer­tain…...

Google News
endpoints.news > novartis-car-t-deaths-raise-questions-over-acceptable-autoimmune-risk

Novartis CAR-T deaths raise questions over acceptable autoimmune risk

1+ week, 4+ day ago   (96+ words) Deaths in Novartis CAR-T trial force a reckoning over acceptable risk in autoimmune disease Endpoints News Deaths in No­var­tis CAR-T tri­al force a reck­on­ing over ac­cept­able risk in au­toim­mune dis­ease…...

Endpoints News
endpoints.news > china-deaths-reignite-debate-about-using-viruses-to-deliver-crispr-therapies

China deaths reignite debate about using viruses to deliver CRISPR therapies

1+ week, 4+ day ago   (85+ words) Endpoints News Chi­na deaths reignite de­bate about us­ing virus­es to de­liv­er CRISPR ther­a­pies The deaths of two chil­dren who re­ceived CRISPR ther­a­pies in Chi­na have rat­tled…...

Endpoints News
endpoints.news > arpa-h-awards-125m-for-manufacturing-custom-rna-therapies-on-demand

ARPA-H awards $125M for manufacturing custom RNA therapies on demand

1+ week, 5+ day ago   (84+ words) Endpoints News ARPA-H awards $125M for man­u­fac­tur­ing cus­tom RNA ther­a­pies on de­mand The dream of mak­ing per­son­al­ized ge­net­ic med­i­cines at a mo­ment’s no­tice…...